These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
358 related articles for article (PubMed ID: 25754088)
1. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Ramkissoon SH; Bi WL; Schumacher SE; Ramkissoon LA; Haidar S; Knoff D; Dubuc A; Brown L; Burns M; Cryan JB; Abedalthagafi M; Kang YJ; Schultz N; Reardon DA; Lee EQ; Rinne ML; Norden AD; Nayak L; Ruland S; Doherty LM; LaFrankie DC; Horvath M; Aizer AA; Russo A; Arvold ND; Claus EB; Al-Mefty O; Johnson MD; Golby AJ; Dunn IF; Chiocca EA; Trippa L; Santagata S; Folkerth RD; Kantoff P; Rollins BJ; Lindeman NI; Wen PY; Ligon AH; Beroukhim R; Alexander BM; Ligon KL Neuro Oncol; 2015 Oct; 17(10):1344-55. PubMed ID: 25754088 [TBL] [Abstract][Full Text] [Related]
2. Copy Number Profiling of Brazilian Astrocytomas. Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220 [TBL] [Abstract][Full Text] [Related]
3. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030 [TBL] [Abstract][Full Text] [Related]
4. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350 [TBL] [Abstract][Full Text] [Related]
5. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882 [TBL] [Abstract][Full Text] [Related]
6. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling. McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748 [TBL] [Abstract][Full Text] [Related]
7. Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Byeon SJ; Cho HJ; Baek HW; Park CK; Choi SH; Kim SH; Kim HK; Park SH Hum Pathol; 2014 Mar; 45(3):611-20. PubMed ID: 24457079 [TBL] [Abstract][Full Text] [Related]
8. Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil. Koshiyama DB; Trevisan P; Graziadio C; Rosa RFM; Cunegatto B; Scholl J; Provenzi VO; de Sá AP; Soares FP; Velho MC; de A P Filho N; Oliveira CA; Zen PRG J Neurooncol; 2017 Dec; 135(3):465-472. PubMed ID: 28856550 [TBL] [Abstract][Full Text] [Related]
9. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203 [TBL] [Abstract][Full Text] [Related]
10. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Ramkissoon SH; Bandopadhayay P; Hwang J; Ramkissoon LA; Greenwald NF; Schumacher SE; O'Rourke R; Pinches N; Ho P; Malkin H; Sinai C; Filbin M; Plant A; Bi WL; Chang MS; Yang E; Wright KD; Manley PE; Ducar M; Alexandrescu S; Lidov H; Delalle I; Goumnerova LC; Church AJ; Janeway KA; Harris MH; MacConaill LE; Folkerth RD; Lindeman NI; Stiles CD; Kieran MW; Ligon AH; Santagata S; Dubuc AM; Chi SN; Beroukhim R; Ligon KL Neuro Oncol; 2017 Jul; 19(7):986-996. PubMed ID: 28104717 [TBL] [Abstract][Full Text] [Related]
11. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886 [TBL] [Abstract][Full Text] [Related]
12. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
13. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation. Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591 [TBL] [Abstract][Full Text] [Related]
14. IDH1 mutation of gliomas with long-term survival analysis. Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798 [TBL] [Abstract][Full Text] [Related]
15. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382 [TBL] [Abstract][Full Text] [Related]
16. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102 [TBL] [Abstract][Full Text] [Related]
17. IDH1/IDH2 but not TP53 mutations predict prognosis in Bulgarian glioblastoma patients. Stancheva G; Goranova T; Laleva M; Kamenova M; Mitkova A; Velinov N; Poptodorov G; Mitev V; Kaneva R; Gabrovsky N Biomed Res Int; 2014; 2014():654727. PubMed ID: 24868540 [TBL] [Abstract][Full Text] [Related]
18. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226 [TBL] [Abstract][Full Text] [Related]